THE USE OF BOTULINUM TOXIN TYPE A FOR THE TREATMENT OF FACIAL PARALYSIS: A NARRATIVE LITERATURE REVIEW

Abstract

Facial paralysis is a neurological condition that compromises the function and symmetry of the facial muscles, impairing patients' quality of life in both personal and functional aspects. Given this, the use of botulinum toxin type A (BoNT-A) has proven to be an effective therapeutic strategy in managing the sequelae of facial paralysis.This study consists of a narrative literature review based on 13 articles published between 2008 and 2024, selected from databases such as PubMed, SciELO, Google Scholar, and ScienceDirect, according to specific inclusion and exclusion criteria. The review highlighted the distinct viewpoints of the authors, and the results indicate that the application of BoNT-A contributes to improved facial symmetry, reduced synkinesis, and enhanced quality of life and self-esteem of patients. Furthermore, it shows potential as an adjuvant treatment in combined protocols. However, challenges remain regarding the standardization of doses and injection sites. Therefore, it is concluded that BoNT-A is a promising approach in the treatment of facial paralysis, although further studies are needed to standardize protocols and optimize outcomes.